BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has entered into a definitive agreement to acquire Alesta Therapeutics, a clinical-stage biotechnology company, to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE